For FY18, $SYK expects its organic sales growth to be in the range of 6.0- 6.5%. Adj. EPS is expected to be in the range of $7.07-7.17. For 1Q18, the company expects its Adj. EPS to be about $1.57-1.62.

Surgical equipment manufacturer $SYK slipped into loss during 4Q17, following the passage of the new tax legislation. Net loss during the quarter was $249MM, or $0.66 per share, compared to earnings of $510MM, or $1.34 per share in the prior year period. Adj. EPS rose 10.1% to $1.96. Net sales, however rose 10.0% YoY to $3.5Bil in 4Q17.

$SYK said that for 4Q17 its preliminary results are of net sales growth of 10% to $3.5Bil, while for FY17, its net sales grew 9.9% to $12.4Bil. Excluding the impact of foreign currency & acquisitions, net sales rose 8.1% and 7.1% in 4Q17 and FY17. For 2018, $SYK expects modest headwinds that will be manageable within its overall financial targets.

$SYK said Howard Cox Jr. has notified the company that he will not stand for re-election at Stryker's 2018 Annual Meeting, which is expected to be held on May 2, 2018. In light of Cox's immense contributions to the company, he will be named Director Emeritus.

$SYK said that the simplified public tender offer for the shares and BSAAR warrants of VEXIM has closed. $SYK, which already owned over 50% of the share capital and voting rights of VEXIM, acquired an additional 4.04MM shares during the offer period, as well as 226,520 BSAAR warrants that it has exercised for new shares of VEXIM.

Rowley Law PLLC is investigating potential claims against $ENTL and its BoD for breach of fiduciary duty concerning the proposed acquisition of the company by $SYK. Stockholders will receive $24.00 in cash for each share of $ENTL that they hold. The transaction is valued at about $662MM.

$SYK agreed to buy $ENTL for $24 per share, or an equity value of about $662MM. The transaction is expected to be dilutive to $SYK's 2018 adjusted EPS by about $0.04 and accretive thereafter. Guggenheim Securities served as financial advisor and Skadden, Arps, Slate, Meagher & Flom LLP served as outside legal counsel for $SYK.

$SYK BoD declared a quarterly dividend of $0.47 per share payable on January 31, 2018 to shareholders of record on December 29, 2017. This  represents an increase of approx. 11% compared to the prior year and the previous quarter.

$SYK, which is seeing a steady growth in the surgical booms market, reported a 6.1% jump in revenue to $3Bil for the second quarter of 2017.  Stryker’s revenue from Neurotechnology rose 13% to $352MM.

Surgical equipment manufacturer $SYK posted a 2.9% increase in net earnings to $391MM for the second quarter of 2017, compared to a year ago period. Organic net sales growth for 2017 is expected to be in the range of 6.5-7.0% and adjusted EPS to be in the range of $6.45-6.55.

$SYK agreed to buy $NVDQ. The transaction is expected to be dilutive to $SYK's 2017 adjusted EPS by $0.03-0.05. There is no change in $SYK's 2017 adjusted EPS forecast of $6.35-6.45. For 2018, this transaction is expected to be neutral to $SYK's earnings and accretive thereafter.

$SYK agreed to buy $NVDQ for $11.75 per share, or $701MM with a net purchase price of $654MM, reflecting net cash of about $47MM. The transaction is expected to close at the end of 3Q17.

$GE's GE Additive and $SYK have entered a partnership agreement to support $SYK's growth in additive manufacturing. The agreement covers new additive machines, materials and services for $SYK's global supply chain operations.

$SYK said its subsidiary Howmedica Osteonics will move forward with the 2016 Settlement Program that provides for compensation to additional eligible U.S. patients who had surgery to replace their Rejuvenate Modular-Neck hip stem and/or ABG II Modular-Neck hip stem, known as a revision surgery, prior to Dec. 19, 2016.

$SYK said its subsidiary Howmedica Osteonics has informed the courts in the New Jersey Multicounty and Federal Multidistrict litigations that 95% of additional registered eligible patients have enrolled in the Settlement Program under the Master Settlement Agreement announced in December 2016.

$SYK's BoD declared a quarterly dividend of $0.425 per share, payable on July 31, 2017 to shareholders of record on June 30, 2017. This represents an increase of 12% versus the prior year and unchanged from the previous quarter.